NCT00304265View on ClinicalTrials.gov

Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine

PHASE4CompletedINTERVENTIONAL

Enrollment

215

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

October 31, 2006

Study Completion Date

October 31, 2007

Conditions

PertussisDiphtheriaTetanusPoliomyelitis

Interventions

BIOLOGICAL

COVAXIS™: Tetanus, diphtheria, acellular 5-component pertussis, or + inactivated poliovirus vaccine (REPEVAX®)

0.5 mL, Intramuscular

Trial Locations (17)

D-80337

Munich

D-33611

Bielefeld

D-32756

Detmold

D-73072

Donzdorf

D-85567

Grafing

D-74072

Heilbronn

D-74348

Lauffen am Neckar

D-71672

Marbach

D-87616

Marktoberdorf

D-80939

Munich

D-81247

Munich

D-92421

Schwandorf in Bayern

D-74523

Schwäbisch Hall

D-71701

Schwieberdingen

D-70469

Stuttgart

D-73079

Süßen

D-97209

Veitshöchheim

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00304265 - Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine | Biotech Hunter | Biotech Hunter